As previously reported, Deutsche Bank downgraded Argenx (ARGX) to Hold from Buy with an unchanged price target of EUR 655. The firm, which notes that the stock price is up more than 40% since its pre-Q2 upgrade two months ago, tells investors that it is trying to be “reasonably disciplined” with its valuation and price target framework.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx’s Phase 3 Study on Efgartigimod: A Potential Game-Changer in Autoimmune Treatment
- Argenx Advances in Systemic Sclerosis Treatment with Efgartigimod PH20 SC Study
- Argenx’s Phase 3 Study on Empasiprubart: A Potential Game-Changer for MMN Treatment?
- Argenx’s CIDP Study: Transitioning from IVIg to Efgartigimod PH20 SC
- Argenx Advances Pediatric gMG Treatment with Efgartigimod Study